Basar Bilgicer

Basar Bilgicer

High Res Photo

Associate Professor

Office: 205C McCourtney Hall
Phone: 574-631-1429
Email: bbilgicer@nd.edu

Visit Website

WWYFF Feature

Areas of Expertise

Biochemistry, multivalent biomolecular interactions, design of multivalent therapeutic and diagnostic molecules

Basar Bilgicer is an Associate Professor in the Department of Chemical and Biomolecular Engineering as well as the Department of Chemistry and Biochemistry. Currently, his group uses his expertise in bioengineering, biophysical chemistry, synthetic chemistry, and targeted drug delivery to find answers to a variety of diseases. As part of his research program, his group is using the principles of multivalent biomolecular interactions to design nanoparticulate therapeutic agents with enhanced targeting selectivity in cancers such as multiple myeloma, breast and ovarian cancer. His group has developed new methods to investigate allergic responses at the biomolecular level with high precision, and has been working on the development of selective bivalent inhibitors of type-I hypersensitivity. Furthermore, his group’s studies on antibody valency and structure led to development of several technologies including enhancing sensing in biosensors and new tools for antibody purification. Several of his published work has been highlighted in media outlets such as BBC Knowledge, C&EN News, ACS Nano, Nature SciBX, Materials Today, Nanomedicine, Pharmaceutical Formulations, Genetic Engineering and Biotechnology News, Science Daily, Nano Magazine UK, and HemOnc Today. He recently has been the recipient of Hollis Brownstein Research Program Award from the Leukemia Research Foundation.

ND NEWSWIRE ARTICLES

Cancer treatment system wins 2016 McCloskey Business Plan Competition

Notre Dame and Loyola join forces against cancer

Notre Dame researchers make progress toward a treatment for dangerous allergies

Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment

Researchers engineer new way to inhibit allergic reactions without side effects

Researcher Bilgicer using nanotechnology to improve cancer treatment

Notre Dame researchers receive medical technologies grants for Indiana-based initiatives